Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Global Intensity-modulated Radiotherapy Market, Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. The global ...

For patients with stage III or IV oropharyngeal cancer, intensity-modulated proton therapy (IMPT) is noninferior to intensity ...

Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung cancer (NSCLC), as it reduces radiation exposure to the ...

SAN FRANCISCO, September 29, 2025 — A new phase III clinical trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low ...

Vancouver, Oct. 24, 2023 (GLOBE NEWSWIRE) -- The global Intensity Modulated Radiotherapy (IMRT) market size was USD 2.21 Billion in 2022 and is expected to register a steady revenue CAGR of 5.4% ...

According to preliminary data from a multi-institution Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, intensity modulated proton therapy (IMPT) achieved ...

Proton radiotherapy (RT) for oropharyngeal cancer matched conventional photon therapy for slowing disease progression and led ...

Please provide your email address to receive an email when new articles are posted on . Risk for late feeding tube dependence was low and did not differ between intensity-modulated radiation therapy ...

Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

USA: A large US-based phase III clinical trial has shown that proton radiotherapy offers a meaningful survival advantage and ...